Celldex Therapeutics, Inc. Share Price Nasdaq
Stocks
US15117B1035
Biotechnology & Medical Research
| Market Cap | 215.37Cr 196.16Cr 180.75Cr 164.42Cr 308.45Cr 20TCr 324.18Cr 2.2TCr 874.34Cr 11TCr 808.07Cr 791.03Cr 34TCr | P/E 2026 * |
-6.66x | P/E 2027 * | -6.81x |
|---|---|---|---|---|---|
| Enterprise Value | 156.06Cr 142.14Cr 130.98Cr 119.14Cr 223.51Cr 14TCr 234.91Cr 1.59TCr 633.58Cr 7.89TCr 585.55Cr 573.21Cr 25TCr | EV / Sales 2026 * |
1,127x | EV / Sales 2027 * | 211x |
| Free-Float |
99.73% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Celldex Therapeutics, Inc.
| 1 day | +10.82% |
| Manager | Title | Age | Since |
|---|---|---|---|
Tibor Keler
CTO | Chief Tech/Sci/R&D Officer | 67 | 30/07/2014 |
Anthony Marucci
CEO | Chief Executive Officer | 64 | 01/09/2008 |
Sam Martin
DFI | Director of Finance/CFO | 55 | 01/04/2009 |
| Director | Title | Age | Since |
|---|---|---|---|
Anthony Marucci
BRD | Director/Board Member | 64 | 01/12/2008 |
Harry Penner
CHM | Chairman | 80 | 05/06/2025 |
Herbert Conrad
BRD | Director/Board Member | 93 | 01/03/2008 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +10.82% | +992.89% | - | - | 215.37Cr | ||
| -2.49% | -3.76% | +50.31% | +62.10% | 6.37TCr | ||
| -0.63% | -2.91% | +6.20% | +89.22% | 5.86TCr | ||
| -2.37% | -2.22% | +22.87% | +82.31% | 5.42TCr | ||
| -2.19% | -6.15% | +11.92% | +108.08% | 4.47TCr | ||
| -1.89% | -7.28% | +13.22% | +19.74% | 4.05TCr | ||
| -0.93% | -0.47% | +19.73% | +43.75% | 3.63TCr | ||
| +1.11% | -6.44% | +130.68% | +641.83% | 3.49TCr | ||
| -0.80% | +0.61% | +77.26% | +56.26% | 3.23TCr | ||
| -2.17% | +16.65% | -29.21% | +474.05% | 3.1TCr | ||
| Average | -0.15% | -1.22% | +33.67% | +175.26% | 4TCr | |
| Weighted average by Cap. | -1.41% | -1.85% | +32.16% | +150.90% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 13.85L 12.61L 11.62L 10.57L 19.83L 13Cr 20.84L 1.41Cr 56.21L 7Cr 51.95L 50.85L 22Cr | 70.72L 64.42L 59.36L 53.99L 1.01Cr 65Cr 1.06Cr 7.22Cr 2.87Cr 36Cr 2.65Cr 2.6Cr 112.26Cr |
| Net income | -31Cr -28Cr -26Cr -24Cr -44Cr -2.86TCr -46Cr -315.37Cr -125.34Cr -1.56TCr -115.84Cr -113.4Cr -4.9TCr | -34Cr -31Cr -28Cr -26Cr -48Cr -3.11TCr -51Cr -343.15Cr -136.38Cr -1.7TCr -126.05Cr -123.39Cr -5.33TCr |
| Net Debt | -59Cr -54Cr -50Cr -45Cr -85Cr -5.49TCr -89Cr -605.77Cr -240.76Cr -3TCr -222.52Cr -217.82Cr -9.41TCr | -66Cr -60Cr -55Cr -50Cr -95Cr -6.11TCr -99Cr -674.43Cr -268.05Cr -3.34TCr -247.74Cr -242.51Cr -10TCr |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
















